Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 129-140

  Komm, Barry S ^a   Mirkin, Sebastian ^a  

^a PFIZER INC   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Menopause; Osteoporosis; Tissue selective estrogen complex; Vasomotor symptoms

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; LASOFOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

BONE DENSITY; BONE TURNOVER; BREAST DISEASE; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; HOT FLUSH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MAMMOGRAPHY; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PATIENT SATISFACTION; POSTMENOPAUSE; PROTHROMBIN TIME; QUALITY OF LIFE; REVIEW; SLEEP QUALITY; UTERUS BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 84859458477     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s29346     Document Type: Review

References (53)

1. Burger HG. The endocrinology of the menopause. Maturitas. 1996;23(2): 129-136.
2. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006;96(7):1226-1235.
3. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94.
4. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763-773.
5. Lewis V. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr Med Res Opin. 2009;25(11): 2689-2698.
6. National Osteoporosis Foundation. Fast Facts on Osteoporosis. 2010. Available from: http://www.nof.org/node/40. Accessed November 17, 2011.
7. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.
8. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4: CD001500.
9. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause. 2006;13(6): 917-925.
10. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1): 25-54.
11. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(2): 242-255.
12. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338(8762):274-277.
13. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131-1137.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
15. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause. 2005;12(4):399-404.
16. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008; 149(12): 6084-6091.
17. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001;949:317-326.
18. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146(9): 3999-4008.
19. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009;23:75-85.
20. Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol. 2010;118(1-2):117-124.
21. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. Activity of three selective estrogen receptor modulators on hormonedependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol. 2008;287(1-2):40-46.
22. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009;150(4):1897-1903.
23. Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone. 2011;49(3):376-386.
24. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92(3):1025-1038.
25. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92(3):1039-1044.
26. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92(3):1045-1052.
27. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3): 1018-1024.
28. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116-1124.
29. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281-289.
30. Dreyer P, Vieira JG. Bone turnover assessment: a good surrogate marker? Arq Bras Endocrinol Metabol. 2010;54(2):99-105.
31. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst. 2000;92(13):1081-1087.
32. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159-1169.
33. Harvey JA, Pinkerton JV, Baracat EC, Shi H, Mirkin S, Chines AA. Evaluation of changes in mammographic breast density associated with bazedoxifene/conjugated estrogens in postmenopausal women. Endocr Rev. 2011;32(3):P1-P79.
34. Pinkerton JA, Constantine GD, Komm BS, Yu H, Pickar JH. Breast effects of bazedoxifene/conjugated estrogens in a randomized, controlled trial of postmenopausal women. Poster presented at: The 19th Annual Meeting of the North American Menopause Society; September 24-27, 2008; Lake Buena Vista, FL, USA; 2008. Abstract P-46.
35. Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause. 2010;17(6):1221-1222.
36. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol. 1997;11(5): 341-355.
37. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol. 1994;29(3-4):319-336.
38. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause. 2010;17(6):1237-1238.
39. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63(4):329-335.
40. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE). Menopause. 2010;17(6):1219.
41. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132-140.
42. Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res. 2006;32(3):305-308.
43. Martin LJ, Minkin S, Boyd NF. Hormone therapy, mammographic density, and breast cancer risk. Maturitas. 2009;64(1):20-26.
44. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst. 2001;93(1): 51-56.
45. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005;105:1063-1073.
46. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76(1):13-24.
47. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348(19): 1839-1854.
48. Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med. 2005;165(17):1976-1986.
49. Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol. 1998;178(5):1002-1009.
50. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100(6):1209-1218.
51. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause. 2003;10(1):29-36.
52. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/ Progestin Replacement Study (HERS) trial. JAMA. 2002;287(5): 591-597.
53. Haines CJ, Yim SF, Chung TK, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas. 2003;44(3):207-214.